Cargando…
Targeting of Protein Kinase CK2 in Acute Myeloid Leukemia Cells Using the Clinical-Grade Synthetic-Peptide CIGB-300
Protein kinase CK2 has emerged as an attractive therapeutic target in acute myeloid leukemia (AML), an advent that becomes particularly relevant since the treatment of this hematological neoplasia remains challenging. Here we explored for the first time the effect of the clinical-grade peptide-based...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8301452/ https://www.ncbi.nlm.nih.gov/pubmed/34356831 http://dx.doi.org/10.3390/biomedicines9070766 |
_version_ | 1783726673151131648 |
---|---|
author | Rosales, Mauro Pérez, George V. Ramón, Ailyn C. Cruz, Yiliam Rodríguez-Ulloa, Arielis Besada, Vladimir Ramos, Yassel Vázquez-Blomquist, Dania Caballero, Evelin Aguilar, Daylen González, Luis J. Zettl, Katharina Wiśniewski, Jacek R. Yang, Ke Perera, Yasser Perea, Silvio E. |
author_facet | Rosales, Mauro Pérez, George V. Ramón, Ailyn C. Cruz, Yiliam Rodríguez-Ulloa, Arielis Besada, Vladimir Ramos, Yassel Vázquez-Blomquist, Dania Caballero, Evelin Aguilar, Daylen González, Luis J. Zettl, Katharina Wiśniewski, Jacek R. Yang, Ke Perera, Yasser Perea, Silvio E. |
author_sort | Rosales, Mauro |
collection | PubMed |
description | Protein kinase CK2 has emerged as an attractive therapeutic target in acute myeloid leukemia (AML), an advent that becomes particularly relevant since the treatment of this hematological neoplasia remains challenging. Here we explored for the first time the effect of the clinical-grade peptide-based CK2 inhibitor CIGB-300 on AML cells proliferation and viability. CIGB-300 internalization and subcellular distribution were also studied, and the role of B23/nucleophosmin 1 (NPM1), a major target for the peptide in solid tumors, was addressed by knock-down in model cell lines. Finally, pull-down experiments and phosphoproteomic analysis were performed to study CIGB-interacting proteins and identify the array of CK2 substrates differentially modulated after treatment with the peptide. Importantly, CIGB-300 elicited a potent anti-proliferative and proapoptotic effect in AML cells, with more than 80% of peptide transduced cells within three minutes. Unlike solid tumor cells, NPM1 did not appear to be a major target for CIGB-300 in AML cells. However, in vivo pull-down experiments and phosphoproteomic analysis evidenced that CIGB-300 targeted the CK2α catalytic subunit, different ribosomal proteins, and inhibited the phosphorylation of a common CK2 substrates array among both AML backgrounds. Remarkably, our results not only provide cellular and molecular insights unveiling the complexity of the CIGB-300 anti-leukemic effect in AML cells but also reinforce the rationale behind the pharmacologic blockade of protein kinase CK2 for AML-targeted therapy. |
format | Online Article Text |
id | pubmed-8301452 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-83014522021-07-24 Targeting of Protein Kinase CK2 in Acute Myeloid Leukemia Cells Using the Clinical-Grade Synthetic-Peptide CIGB-300 Rosales, Mauro Pérez, George V. Ramón, Ailyn C. Cruz, Yiliam Rodríguez-Ulloa, Arielis Besada, Vladimir Ramos, Yassel Vázquez-Blomquist, Dania Caballero, Evelin Aguilar, Daylen González, Luis J. Zettl, Katharina Wiśniewski, Jacek R. Yang, Ke Perera, Yasser Perea, Silvio E. Biomedicines Article Protein kinase CK2 has emerged as an attractive therapeutic target in acute myeloid leukemia (AML), an advent that becomes particularly relevant since the treatment of this hematological neoplasia remains challenging. Here we explored for the first time the effect of the clinical-grade peptide-based CK2 inhibitor CIGB-300 on AML cells proliferation and viability. CIGB-300 internalization and subcellular distribution were also studied, and the role of B23/nucleophosmin 1 (NPM1), a major target for the peptide in solid tumors, was addressed by knock-down in model cell lines. Finally, pull-down experiments and phosphoproteomic analysis were performed to study CIGB-interacting proteins and identify the array of CK2 substrates differentially modulated after treatment with the peptide. Importantly, CIGB-300 elicited a potent anti-proliferative and proapoptotic effect in AML cells, with more than 80% of peptide transduced cells within three minutes. Unlike solid tumor cells, NPM1 did not appear to be a major target for CIGB-300 in AML cells. However, in vivo pull-down experiments and phosphoproteomic analysis evidenced that CIGB-300 targeted the CK2α catalytic subunit, different ribosomal proteins, and inhibited the phosphorylation of a common CK2 substrates array among both AML backgrounds. Remarkably, our results not only provide cellular and molecular insights unveiling the complexity of the CIGB-300 anti-leukemic effect in AML cells but also reinforce the rationale behind the pharmacologic blockade of protein kinase CK2 for AML-targeted therapy. MDPI 2021-07-01 /pmc/articles/PMC8301452/ /pubmed/34356831 http://dx.doi.org/10.3390/biomedicines9070766 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Rosales, Mauro Pérez, George V. Ramón, Ailyn C. Cruz, Yiliam Rodríguez-Ulloa, Arielis Besada, Vladimir Ramos, Yassel Vázquez-Blomquist, Dania Caballero, Evelin Aguilar, Daylen González, Luis J. Zettl, Katharina Wiśniewski, Jacek R. Yang, Ke Perera, Yasser Perea, Silvio E. Targeting of Protein Kinase CK2 in Acute Myeloid Leukemia Cells Using the Clinical-Grade Synthetic-Peptide CIGB-300 |
title | Targeting of Protein Kinase CK2 in Acute Myeloid Leukemia Cells Using the Clinical-Grade Synthetic-Peptide CIGB-300 |
title_full | Targeting of Protein Kinase CK2 in Acute Myeloid Leukemia Cells Using the Clinical-Grade Synthetic-Peptide CIGB-300 |
title_fullStr | Targeting of Protein Kinase CK2 in Acute Myeloid Leukemia Cells Using the Clinical-Grade Synthetic-Peptide CIGB-300 |
title_full_unstemmed | Targeting of Protein Kinase CK2 in Acute Myeloid Leukemia Cells Using the Clinical-Grade Synthetic-Peptide CIGB-300 |
title_short | Targeting of Protein Kinase CK2 in Acute Myeloid Leukemia Cells Using the Clinical-Grade Synthetic-Peptide CIGB-300 |
title_sort | targeting of protein kinase ck2 in acute myeloid leukemia cells using the clinical-grade synthetic-peptide cigb-300 |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8301452/ https://www.ncbi.nlm.nih.gov/pubmed/34356831 http://dx.doi.org/10.3390/biomedicines9070766 |
work_keys_str_mv | AT rosalesmauro targetingofproteinkinaseck2inacutemyeloidleukemiacellsusingtheclinicalgradesyntheticpeptidecigb300 AT perezgeorgev targetingofproteinkinaseck2inacutemyeloidleukemiacellsusingtheclinicalgradesyntheticpeptidecigb300 AT ramonailync targetingofproteinkinaseck2inacutemyeloidleukemiacellsusingtheclinicalgradesyntheticpeptidecigb300 AT cruzyiliam targetingofproteinkinaseck2inacutemyeloidleukemiacellsusingtheclinicalgradesyntheticpeptidecigb300 AT rodriguezulloaarielis targetingofproteinkinaseck2inacutemyeloidleukemiacellsusingtheclinicalgradesyntheticpeptidecigb300 AT besadavladimir targetingofproteinkinaseck2inacutemyeloidleukemiacellsusingtheclinicalgradesyntheticpeptidecigb300 AT ramosyassel targetingofproteinkinaseck2inacutemyeloidleukemiacellsusingtheclinicalgradesyntheticpeptidecigb300 AT vazquezblomquistdania targetingofproteinkinaseck2inacutemyeloidleukemiacellsusingtheclinicalgradesyntheticpeptidecigb300 AT caballeroevelin targetingofproteinkinaseck2inacutemyeloidleukemiacellsusingtheclinicalgradesyntheticpeptidecigb300 AT aguilardaylen targetingofproteinkinaseck2inacutemyeloidleukemiacellsusingtheclinicalgradesyntheticpeptidecigb300 AT gonzalezluisj targetingofproteinkinaseck2inacutemyeloidleukemiacellsusingtheclinicalgradesyntheticpeptidecigb300 AT zettlkatharina targetingofproteinkinaseck2inacutemyeloidleukemiacellsusingtheclinicalgradesyntheticpeptidecigb300 AT wisniewskijacekr targetingofproteinkinaseck2inacutemyeloidleukemiacellsusingtheclinicalgradesyntheticpeptidecigb300 AT yangke targetingofproteinkinaseck2inacutemyeloidleukemiacellsusingtheclinicalgradesyntheticpeptidecigb300 AT pererayasser targetingofproteinkinaseck2inacutemyeloidleukemiacellsusingtheclinicalgradesyntheticpeptidecigb300 AT pereasilvioe targetingofproteinkinaseck2inacutemyeloidleukemiacellsusingtheclinicalgradesyntheticpeptidecigb300 |